Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Reprod Sci ; 28(8): 2144-2146, 2021 08.
Article in English | MEDLINE | ID: covidwho-1384774

ABSTRACT

Although there is no known difference between the clinical manifestations of SARS-CoV-2 in pregnant and non-pregnant women based on the studies published until now, in vitro fertilization (IVF) treatments were suspended during the pandemic due to uncertainties with the suggestions of associated societies. However, we do not have enough data on the exact effects of SARS-CoV-2 on fertility and pregnancy and whether there are damaging effects on IVF outcome. There is no available evidence about the transmission of SARS-CoV-2 by either sexual way or through intrauterine insemination (IUI) or IVF. Up until now, there is no report to document the presence or absence of viral RNA in follicular fluid of SARS-CoV-2-positive women. In this paper, we present a case of oocyte retrieval from a SARS-CoV-2-positive woman and the search for viral RNA by polymerase chain reaction (PCR) in the follicular fluid aspirates.


Subject(s)
COVID-19 Nucleic Acid Testing , COVID-19/diagnosis , Follicular Fluid/virology , Infertility, Female/therapy , Oocyte Retrieval , RNA, Viral/genetics , SARS-CoV-2/genetics , Sperm Injections, Intracytoplasmic , Adult , COVID-19/virology , Female , Humans , Infertility, Female/diagnosis , Infertility, Female/physiopathology , Predictive Value of Tests
2.
Reprod Biomed Online ; 42(6): 1067-1074, 2021 06.
Article in English | MEDLINE | ID: covidwho-1169278

ABSTRACT

RESEARCH QUESTION: Is there a risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral exposure and potential cross-contamination from follicular fluid, culture media and vitrification solution within the IVF laboratory using strict patient screening and safety measures? DESIGN: This was a prospective clinical study. All women undergoing transvaginal oocyte retrieval were required to have a negative SARS-CoV-2 RNA test 3-5 days prior to the procedure. Male partners were not tested. All cases used intracytoplasmic sperm injection (ICSI). The first tube of follicular fluid aspirated during oocyte retrieval, drops of media following removal of the embryos on day 5, and vitrification solution after blastocyst cryopreservation were analysed for SARS-CoV-2 RNA. RESULTS: In total, medium from 61 patients, vitrification solution from 200 patients and follicular fluid from 300 patients was analysed. All samples were negative for SARS-CoV-2 viral RNA. CONCLUSIONS: With stringent safety protocols in place, including testing of women and symptom-based screening of men, the presence of SARS-CoV-2 RNA was not detected in follicular fluid, medium or vitrification solution. This work demonstrates the possibility of implementing a rapid laboratory screening assay for SARS-CoV-2 and has implications for safe laboratory operations, including cryostorage recommendations.


Subject(s)
Culture Media/analysis , Fertilization in Vitro , Follicular Fluid/virology , Laboratories , RNA, Viral/isolation & purification , SARS-CoV-2/isolation & purification , Female , Humans , Oocyte Retrieval , Patient Safety , Prospective Studies , Sperm Injections, Intracytoplasmic , Vitrification
SELECTION OF CITATIONS
SEARCH DETAIL